Low-molecular-weight heparin therapy in children

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 2, 2000, Pages 98-99

  Massicotte, M Patricia ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A ANTIBODY; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; BLEEDING; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEPARINIZATION; HUMAN; META ANALYSIS; NOTE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT INDICATION; VASCULAR ACCESS;

ANIMALS; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; ENOXAPARIN; HUMANS; INFANT; MOLECULAR WEIGHT; THROMBOEMBOLISM;

EID: 0034457399     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200003000-00002     Document Type: Editorial

References (14)

1. Andrew M, Adams D, David M, et al. Venous thromboembolic complications (VTE) in children: First analysis of the Canadian Registry of VTE. Blood 1994;83:1251-7.
2. Michelson A, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. Chest 1998;114:7485-695.
3. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995:108:258S-75.
4. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res 1994:35:78-83.
5. Hirsh J. Heparin. N Engl J Med 1991:324:1565-74.
6. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999;94:3007-14.
7. Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: A potential complication of warfarin therapy. Thromb Haemost 1999;(Suppl):422.
8. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
9. Andrew M, Ofusu F, Brooker L, et al. The comparison of the pharmacokinetics of a low-molecular-weight heparin in the newborn and adult pig. Thromb Res 1989;56:529-39.
10. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose-finding study. J Pediatr 1996;128:313-8.
11. Dix D, Andrew M, Marzinotto V, et al. The use of low-molecular-weight heparin in paediatric patients: A prospective cohort study with clinical outcomes. J Pediatr (in press).
12. Massicotte P, Adams M, Leaker M, Andrew M. A nomogram to establish therapeutic levels of the low-molecular-weight heparin Clivarine in children requiring treatment for venous thromboembolism. Thromb Haemost 1997;(Suppl):282.
13. Massicotte P, Marzinotto V, Julian J, et al. Dose finding and pharmacokinetics of prophylaxis doses of a low-molecular-weight heparin (reviparin) in pediatric patients.
14. Punzalen RC, Hillery CA, Montgomery RR, et al. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000;22(2):137-42.